CN111447940A - 预防或治疗由辐射或放射疗法引起的辐射诱发的旁观者效应的组合物和方法 - Google Patents

预防或治疗由辐射或放射疗法引起的辐射诱发的旁观者效应的组合物和方法 Download PDF

Info

Publication number
CN111447940A
CN111447940A CN201880060319.XA CN201880060319A CN111447940A CN 111447940 A CN111447940 A CN 111447940A CN 201880060319 A CN201880060319 A CN 201880060319A CN 111447940 A CN111447940 A CN 111447940A
Authority
CN
China
Prior art keywords
radiation
subject
quercetin
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880060319.XA
Other languages
English (en)
Chinese (zh)
Inventor
D·薛
Y·彭
M·张
L·J·郑
Q·梁
H·Z·李
J-S·于
J-T·陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Colorado
Original Assignee
University Colorado
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Colorado filed Critical University Colorado
Publication of CN111447940A publication Critical patent/CN111447940A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
CN201880060319.XA 2017-07-17 2018-07-17 预防或治疗由辐射或放射疗法引起的辐射诱发的旁观者效应的组合物和方法 Pending CN111447940A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762533272P 2017-07-17 2017-07-17
US62/533,272 2017-07-17
PCT/US2018/042569 WO2019018451A2 (en) 2017-07-17 2018-07-17 COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED PROXIMITY EFFECTS CAUSED BY RADIATION OR RADIATION THERAPY

Publications (1)

Publication Number Publication Date
CN111447940A true CN111447940A (zh) 2020-07-24

Family

ID=65015329

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880060319.XA Pending CN111447940A (zh) 2017-07-17 2018-07-17 预防或治疗由辐射或放射疗法引起的辐射诱发的旁观者效应的组合物和方法

Country Status (6)

Country Link
US (2) US11452709B2 (https=)
EP (1) EP3655015B1 (https=)
JP (2) JP7598137B2 (https=)
CN (1) CN111447940A (https=)
CA (1) CA3069701A1 (https=)
WO (1) WO2019018451A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112553286A (zh) * 2020-11-05 2021-03-26 北京大学深圳医院 自杀基因/前药系统疗效的评价方法和药物筛选方法
CN114150054A (zh) * 2021-12-03 2022-03-08 中国科学院近代物理研究所 检测或评估电离辐射损伤或暴露的试剂及其所用tRNA衍生片段
CN114350787A (zh) * 2022-01-12 2022-04-15 中国人民解放军军事科学院军事医学研究院 一种ATE1的RNA m6A修饰作为γ射线辐射标志物的应用
CN114392255A (zh) * 2021-11-10 2022-04-26 甘肃中医药大学 乌拉尔醇的新应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3069701A1 (en) 2017-07-17 2019-01-24 The Regents Of The University Of Colorado Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy
KR102817623B1 (ko) * 2021-05-14 2025-06-10 한국원자력의학원 방사선 치료 예후 예측용 또는 방사선 저항성 암 진단용 바이오마커 조성물
CN119185555B (zh) * 2024-11-27 2025-04-04 浙江大学 一种用于干预捻转血矛线虫群体性别比例的siRNA及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101365806A (zh) * 2005-12-01 2009-02-11 医学预后研究所 用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途
CN101907614A (zh) * 2010-07-26 2010-12-08 中国科学院长春应用化学研究所 超高效液相色谱和质谱联用筛选组织蛋白酶b抑制剂的方法
CN101969973A (zh) * 2008-02-07 2011-02-09 维罗贝股份有限公司 组织蛋白酶b抑制剂
CN103038360A (zh) * 2010-07-02 2013-04-10 帕普斯特许可有限两合公司 测定生物样品中蛋白酶的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
MC2115A1 (fr) 1987-12-15 1991-07-05 Gene Shears Pty Ltd Ribozynes
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5244805A (en) 1989-05-17 1993-09-14 University Of Georgia Research Foundation, Inc. Baculovirus expression vectors
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5723750A (en) 1995-01-12 1998-03-03 Vanderbilt University Transgenic plants expressing disassembly deficient viral coat proteins
US6278039B1 (en) 1997-05-28 2001-08-21 Axys Pharmaceuticals, Inc. C. elegans deletion mutants
US6251588B1 (en) 1998-02-10 2001-06-26 Agilent Technologies, Inc. Method for evaluating oligonucleotide probe sequences
US6110462A (en) 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
WO2008106463A1 (en) 2007-02-26 2008-09-04 The Board Of Trustees Of The Univerity Of Illinois Phenylalanine for plant protection against uv radiation
IT1393841B1 (it) 2009-04-30 2012-05-11 Giuliani Spa Composizione farmaceutica o dermatologica o nutrizionale o cosmetica per combattere l'azione di immunosoppressione provocata sulla pelle da agenti aggressivi
CA3069701A1 (en) 2017-07-17 2019-01-24 The Regents Of The University Of Colorado Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101365806A (zh) * 2005-12-01 2009-02-11 医学预后研究所 用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途
CN101969973A (zh) * 2008-02-07 2011-02-09 维罗贝股份有限公司 组织蛋白酶b抑制剂
CN103038360A (zh) * 2010-07-02 2013-04-10 帕普斯特许可有限两合公司 测定生物样品中蛋白酶的方法
CN101907614A (zh) * 2010-07-26 2010-12-08 中国科学院长春应用化学研究所 超高效液相色谱和质谱联用筛选组织蛋白酶b抑制剂的方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ARIF MALIK等: "Role of Natural Radiosensitizers and Cancer Cell Radioresistance: An Update", 《ANALYTICAL CELLULAR PATHOLOGY》 *
CHRISTOPHER S GONDI等: "Cathepsin B as a cancer target", 《EXPERT OPIN. THER. TARGETS》 *
HAZAN OZYURT等: "Quercetin protects radiation induced DNA damage and apoptosis in kidney and bladder tissues of rat", 《FREE RADICAL RESEARCH》 *
LIAN WANG等: "Quercetin, a flavonoid with anti-inflammatory activity, suppresses the development of abdominal aortic aneurysms in mice", 《EUROPEAN JOURNAL OF PHARMACOLOGY》 *
TAKAE TOWATARI等: "Novel epoxysuccinyl peptides A selective inhibitor of cathepsin B, in vivo", 《FEBS LETTERS》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112553286A (zh) * 2020-11-05 2021-03-26 北京大学深圳医院 自杀基因/前药系统疗效的评价方法和药物筛选方法
CN114392255A (zh) * 2021-11-10 2022-04-26 甘肃中医药大学 乌拉尔醇的新应用
CN114150054A (zh) * 2021-12-03 2022-03-08 中国科学院近代物理研究所 检测或评估电离辐射损伤或暴露的试剂及其所用tRNA衍生片段
CN114350787A (zh) * 2022-01-12 2022-04-15 中国人民解放军军事科学院军事医学研究院 一种ATE1的RNA m6A修饰作为γ射线辐射标志物的应用
CN114350787B (zh) * 2022-01-12 2023-06-30 中国人民解放军军事科学院军事医学研究院 一种ATE1的RNA m6A修饰作为γ射线辐射标志物的应用

Also Published As

Publication number Publication date
EP3655015A4 (en) 2021-04-07
US12447142B2 (en) 2025-10-21
EP3655015B1 (en) 2024-02-21
WO2019018451A2 (en) 2019-01-24
US20230233517A1 (en) 2023-07-27
US20200155502A1 (en) 2020-05-21
WO2019018451A3 (en) 2019-03-14
CA3069701A1 (en) 2019-01-24
JP7598137B2 (ja) 2024-12-11
US11452709B2 (en) 2022-09-27
EP3655015A2 (en) 2020-05-27
JP2023093533A (ja) 2023-07-04
JP2020527569A (ja) 2020-09-10

Similar Documents

Publication Publication Date Title
US12447142B2 (en) Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy
Deng et al. FUS interacts with HSP60 to promote mitochondrial damage
EP2039367B1 (en) Prophylactic/therapeutic agent for neurodegenerative disease
JP2006520326A (ja) 治療薬
US20080242608A1 (en) Methods and compositions for treating and preventing neurologic disorders
JP2002521004A (ja) ヒトβアミドイド前駆体タンパク質（β−ＡＰＰ）のヒトＬＯＮプロテアーゼ様タンパク質（ＨｓＬＯＮ）との相互作用
US9049849B2 (en) Screening methods for compounds useful for treating pancreatic dysfunction
US10188650B2 (en) Treatment of neurological disorders
JP2002520007A (ja) Ｄｅｌｔａ切断産物およびそれに基づく方法
WO2005059100A2 (en) Methods and compositions relating to cystatin c
JP5514443B2 (ja) カテコールアミン調節性タンパク質
EP1678326A2 (en) Genes involved in neurodegenerative disorders
Sevegnani et al. Parkin R274W mutation affects muscle and mitochondrial physiology
JP2007505825A (ja) 増殖性疾患の診断および治療における、細胞周期制御または細胞周期進行に影響を与える真核生物遺伝子の利用
US10017765B2 (en) Inhibitors of CACNA1A/ALPHA1A subunit internal ribosomal entry site (IRES) and methods of treating spinocerebellar ataxia type 6
AU2003231196C1 (en) Androgen-regulated PMEPA1 and cancer
JP2012529282A (ja) 治療薬および分析方法
US20120149645A1 (en) Compositions and modulation of myocyte enhancer factor 2 (mef2)
JP2006516150A (ja) アルツハイマー病の処置法およびそのための組成物
JP2007505826A (ja) 増殖性疾患の診断および治療において、クロマチン分離に影響を与える真核生物遺伝子の使用
JP2005006644A (ja) 新規タンパク質およびそのｄｎａ
JP2006075152A (ja) 細胞移動阻害剤
JPWO2002101035A1 (ja) 新規な電位依存性カチオンチャネル蛋白質
JPWO2005014809A1 (ja) 肝臓ガン特異的ポリペプチド、該ポリペプチドをコードするポリヌクレオチド、及び該ポリペプチドの発現を抑制するｒｎａ分子

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination